

DRUG PRIOR AUTHORIZATION COMMITTEE MEETING
March 18, 2021
MO HealthNet
VIA WEBEX ONLY

Committee Members Present:

Conrad Balcer, DO, Chair
Laura Kingsley, PharmD
Morgan Sperry, PharmD
Angeline Stanislaus, MD

Committee Members Absent:

Matthew Stinson, MD

MO HealthNet Staff Present:

Joshua Moore, PharmD, Director of Pharmacy
Mark Roaseau, R.Ph, Clinical Pharmacist
Angela Wilson, Pharmacy Operations Manager
Elizabeth Sissom, RN, Clinical Management
Lisa E. Smith, Program Development Specialist
Carmen Burton, Administrative Assistant
Timothy Kling, MD, Acting Medical Director
Elizabeth Short, Program Development Specialist
Connie Sutter, Fiscal Manager
Keri Ballew, Drug Rebate Medicaid Specialist
Olivia Rush, PharmD, Program Integrity Pharmacist

Contractors in Attendance:

Jennifer Colozza, PharmD, Conduent
Megan Fast, PharmD, Conduent
Karen Powell, PharmD, Conduent
Serena Barden, PharmD, BCPS, Conduent
Luke Boehmer, PharmD, Conduent
April Ash, PharmD, Conduent
Geri Roling, RN, Wipro
Chelsea Pendleton, RN, BSN, Wipro

Others Attending:

Aaron Shaw
Alex Bitting
Anabelle Keohane
Andrea DeMont
Audrey Rattan
Brandy Vachtsevanos
Brian Strickland
Camille Kerr
Carol White
Casey Eastman
Frank Alvarado
Gina Heinen
Holly Budlong
James Baumann

Jessica Petrie
Joe Cirrincione
Joseph Conoshenti
Justin Terrill
K Gulley
Karen Floeder
Kurt Hendrickson
Lane Anson
L Stout
Maggie Murphy
Mandy Schnelten
Matthew Lennertz
Michael Holmes
Michele Shirley
Mike Chen
Peter Zoob
Phillip King
Rob Hansen
Ryan
Scott Brown
Sean Jones
Terry
Tina Rhinehart
Tom Guyer

<p>Welcome, Introductions and Opening Remarks</p>	<p>Conrad Balcer, Board Chair, called the meeting to order.</p> <p>Joshua Moore introduced himself, and facilitated the meeting on behalf of the MO HealthNet Division.</p>
<p>Minutes Review</p>	<p>Discussion: Minutes were reviewed from the December 2020 meeting.</p> <p>Decision: The committee voted to accept these approved minutes with no revisions.</p>
<p>Pharmacy Program and Budget Update</p>	<p>Elizabeth Short and Joshua Moore presented a brief power point of the Pharmacy Program and Budget Updates. Information presented included:</p> <ul style="list-style-type: none"> - February 2021 Eligibles by Group - July 2020 – February 2021 Expenditures by Enrollment Group - July 2020 – February 2021 Expenditures by Service - FY21 Pharmacy Spend vs July 2020 – February 2021 Total Medicaid Spend - FY21 July 2020 – March 2021 Pharmacy Expenditures - Top 4 Drug Classes per Fiscal Year - FY19 – FYTD2021 Rare Disease Expenditures - July 2020 – March 2021 Rare Disease Expenditures - Sedative Hypnotics PDL Edit Changes July 2020 - Pharmacist as Other Licensed Professionals - COVID Vaccine/Testing Billing and Reimbursement - Tamiflu Utilization Comparison Year over Year - Diabetic Supplies Changes - Medicaid Expansion – Go Live Date expected July 1, 2021
<p>Old Business</p>	
<p>Old Business</p>	<p>Joshua Moore discussed the Edit Implementation Schedule and the criteria for Previously Approved Clinical Edits, Step Therapies and Prior Authorizations.</p> <p>These handouts were also provided to all attendees and will be posted to the Division's web page: https://dss.mo.gov/mhd/cs/advisory/drugpa/meeting.htm</p>

New Business	
New Drug Review	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore reviewed the new products identified for the quarter and the recommended status within the pharmacy program. <ul style="list-style-type: none"> o A listing of products recommended for open access, clinical edit, preferred drug list (PDL), or continue prior authorization was emailed to the Board for discussion and action. - No public comment provided <p>Decision: The committee voted to accept the presented new drug recommendations with no revisions.</p>
Clinical & Fiscal Edits With No Annual Changes	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edits for discussion to the Board which included: <ul style="list-style-type: none"> o Acne or Rosacea, Select Topical Agents Clinical Edit o Givlaari Clinical Edit o Megestrol Clinical Edit o Sickle Cell Disease Clinical Edit o Systemic Antifungals Clinical Edit o Zulresso Clinical Edit - No public comment provided <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators Clinical Edit	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - Public comment provided by: <ul style="list-style-type: none"> o Peter Zoob with MSL Vertex yielded time back. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

<p>Clobazam Agents Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Fabry Disease Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Nocturnal Polyuria Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Opioids, Single Agents Short Acting Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - Questions arose on the number of participants on methadone <ul style="list-style-type: none"> o Roughly 100 new starts per month on methadone however most do not remain long term users - Suggestions: <ul style="list-style-type: none"> o Move new methadone criteria placement within the proposal o Change methadone criteria of “OR” to “AND” to make intentions of additional criteria more clear - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with the additional revision of changing the methadone criteria of “OR” to “AND”</p>

<p align="center">Oxlumo Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Spravato Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Preferred Drug List Edits With No Annual Changes</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edits for discussion to the Board which included: <ul style="list-style-type: none"> o Actinic Keratosis Agents, Topical PDL Edit o Antifungals, Oral PDL Edit PDL Edit o Antihistamines, Intranasal PDL Edit o Antihistamines/Decongestant Combinations, Second Generation PDL Edit o Antivirals, Oral PDL Edit o Antivirals, Topical PDL Edit o Benzoyl Peroxide/Antibiotic Combinations PDL Edit o Beta Adrenergic Agents, Long Acting PDL Edit o Beta Adrenergic Agents, Nebulized PDL Edit o Cough/Cold Preparations PDL Edit o Fluoroquinolones, Ophthalmic PDL Edit o Mast Cell Stabilizers, Ophthalmic PDL Edit o NSAIDs, Ophthalmic PDL Edit o Pancreatic Enzymes PDL Edit o Psoriasis Agents, Oral PDL Edit o Psoriasis Agents, Topical PDL Edit o Retinoids, Topical PDL Edit o Ulcerative Colitis Agents, Rectal PDL Edit - No public comment provided <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

<p>Androgenic Agents PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Antibiotics, Inhaled PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Antifungals, Topical PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Antihistamines, Ophthalmic PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Antiparasitics, Topical PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

<p align="center">Atopic Dermatitis Agents, Immunomodulators, PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - Questions arose on the lower limit for Elidel – specialist currently don't enforce the lower limit for Elidel and the recommendations in the proposal mirror current prescribing habits of MHD providers - Public comment provided by: <ul style="list-style-type: none"> o Andrea DeMont and James Baumann with Pfizer on Eucrisa <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Beta Adrenergics Agents, Short Acting PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - Public comment provided by: <ul style="list-style-type: none"> o Maggie Murphy with Teva on ProAir Digihaler <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">COPD Agents PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - Questions arose on adding the same criteria to similar medications as Trelegy Ellipta – it was explained that the additional criteria for this medication is cost related therefore not needed on others. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Corticosteroids, Inhaled PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - Public comment provided by: <ul style="list-style-type: none"> o Maggie Murphy with Teva on AirDuo Digihaler and ArmonAir Digihaler <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

<p align="center">Corticosteroids, Intranasal PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Corticosteroids, Ophthalmic Soft PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Corticosteroids, Topical PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Epinephrine Agents, Self-Injectable PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - Questions arose on potential penalties for dispensing brand name EpiPen – it was explained brand reimbursement would be given. - Questions arose on the mode of administration between the preferred and non-preferred medications – it was explained that there are no mode of administration factors that differentiate the agents (i.e., talking AuviQ). - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Fluoroquinolones, Otic PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

<p align="center">Glaucoma Agents PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Hepatitis C Agents PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - Additional information was provided in regards to the State’s Hepatitis Elimination Plan. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Hereditary Angioedema (HAE) Agents PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Leukotriene Receptor Modifiers PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - Questions arose on the prior authorization process if a denial diagnosis code was present on a participant profile - it was explained that participant would be granted a one-month override and following the one-month approval, a prior authorization would need to be obtained to continue the medications (i.e., risk vs benefit documentation). - Suggestions on including allergy/asthma diagnosis for approval - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Respiratory Monoclonal Antibodies PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - Public comment provided by: <ul style="list-style-type: none"> o Anabelle Keohane with Sanofi Genzyme on Dupixent <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>

<p>Ulcerative Colitis, Oral PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. - No public comment provided. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions.</p>
<p>Preferred Drug List Announcement</p>	<p>A handout of therapeutic categories to be reviewed for inclusion on the Preferred Drug List for the next phase and March meeting was included in the meeting packet.</p> <p>This handout was also provided to all attendees and will be posted to the Division's web page: https://dss.mo.gov/mhd/cs/advisory/drugpa/meeting.htm</p>
<p>Program Utilization Information – Conduent Update</p>	<p>Jennifer Colozza with Conduent presented the following items for review:</p> <ul style="list-style-type: none"> - Top 25 Drugs by Paid Amount 2nd Quarter 2021 (October, November, December) - Top 25 Drugs by Paid Number 2nd Quarter 2021 (October, November, December) - Call Center User Statistics February 2021 - CyberAccess Logging Information - New Drug Statistics
<p>Adjournment</p>	<p>Morgan Sperry motioned for the meeting to be adjourned. The meeting was adjourned pursuant to Section 610.021 Subsection (14), (5) RSMo for proceedings required pursuant to a disciplinary order concerning medical, psychiatric, psychological, or alcoholism or drug dependency diagnosis or treatment of specific licensees. The next meeting of the Drug Prior Authorization Committee is scheduled via WebEx only on Thursday, June 17, 2021.</p>

Roll Call for March 18, 2021					
	<u>Committee Member</u>				
<u>Action Item</u>	Conrad Balcer	Laura Kingsley	Morgan Sperry	Angeline Stanislaus	Matthew Stinson
December 2020 Minutes	Y	Y	MY	SY	A
New Drug Review	Y	SY	Y	MY	A
Clinical/Fiscal Edit – No Changes	Y	SY	Y	MY	A
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators CE	Y	Y	SY	MY	A
Clobazam Agents CE	Y	MY	Y	SY	A
Fabry Disease CE	Y	SY	Y	MY	A
Nocturnal Polyuria CE	Y	SY	Y	MY	A
Opioids, Single Agents Short Acting CE	Y	SY	Y	MY	A
Oxlumo CE	Y	MY	Y	SY	A
Spravato CE	Y	Y	MY	SY	A
Preferred Drug List Edits With No Annual Changes	Y	SY	Y	MY	A
Androgenic Agents PDL	Y	MY	Y	SY	A
Antibiotics, Inhaled PDL	Y	MY	Y	SY	A

Roll Call for March 18, 2021					
	<u>Committee Member</u>				
<u>Action Item</u>	Conrad Balcer	Laura Kingsley	Morgan Sperry	Angeline Stanislaus	Matthew Stinson
Antifungals, Topical PDL	Y	Y	SY	MY	A
Antihistamines, Ophthalmic PDL	Y	SY	Y	MY	A
Antiparasitics, Topical PDL	Y	MY	Y	SY	A
Atopic Dermatitis Agents, Immunomodulators, PDL	Y	MY	SY	AB	A
Beta Adrenergics Agents, Short Acting PDL	Y	MY	Y	SY	A
COPD Agents PDL	Y	SY	Y	MY	A
Corticosteroids, Inhaled PDL	Y	MY	Y	SY	A
Corticosteroids, Intranasal PDL	Y	SY	Y	MY	A
Corticosteroids, Ophthalmic Soft PDL	Y	Y	MY	SY	A
Corticosteroids, Topical PDL	Y	MY	SY	Y	A
Epinephrine Agents, Self-Injectable PDL	Y	Y	MY	SY	A
Fluoroquinolones, Otic PDL	Y	SY	Y	MY	A
Glaucoma Agents PDL	Y	Y	SY	MY	A

Roll Call for March 18, 2021					
	<u>Committee Member</u>				
<u>Action Item</u>	Conrad Balcer	Laura Kingsley	Morgan Sperry	Angeline Stanislaus	Matthew Stinson
Hepatitis C Agents PDL	Y	MY	Y	SY	A
Hereditary Angioedema (HAE) Agents PDL	Y	SY	Y	MY	A
Leukotriene Receptor Modifiers PDL	Y	MY	SY	Y	A
Respiratory Monoclonal Antibodies PDL	Y	MY	Y	SY	A
Ulcerative Colitis, Oral PDL	Y	MY	SY	Y	A
Motion to Close	Y	Y	MY	SY	A
Adjournment	Y	MY	Y	SY	A

Roll Call Abbreviations: A-Absent; AL-Alternate; R-Ratify; M-Motion; S-Second; Y-Yes; N-No; AB-Abstain